MDS Trials

Luspatercept reduces red blood cell transfusion burden on patients with very low to intermediate risk MDS without negative impact on health-related quality of life

Myelodysplastic syndromes (MDS) are...

Will luspatercept become the new treatment standard after ESA failure in RS-positive LR-MDS patients with TD anemia?

Erythropoiesis-stimulating agents (ESAs) are the standard first-line treatment for...

What is new for MDS with del(5q)?

During the7th European School of Haematology (ESH) Translational Research Conference on Myelodysplastic Syndromes, the MDS Hub spoke to María Díez Campelo,...

Lenalidomide reduces risk of transfusion dependency in lower-risk MDS: Interim results of the Sintra-REV trial

The therapeutic goal for patients with lower-risk myelodysplastic syndrome (MDS) is to...

Imetelstat for patients with highly transfusion-dependent MDS

The initial treatment option for patients with lower-risk MDS is the use of erythropoiesis-stimulating agents (ESAs) with/without other...

Does imetelstat provide transfusion independence in lower-risk MDS?

During the 25th Congress of the European Hematology Association (EHA), the MDS Hub spoke to Uwe Platzbecker, Leipzig University...

Results from the phase II P-2001 study on pevonedistat plus azacytidine for high-risk MDS

To further explore the clinical efficacy and safety of pevo in patients with high-risk MDS, CMML, or low-blast...

P-2001 study: Which patients benefit most from pevonedistat plus azacitidine?

During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the MDS Hub spoke to Mikkael Sekeres,...